POPULARITY
Thanks for listening, and please follow us on Insta @NHPTalent and www.youtube.com/thePOZcastFor all episodes, please check out www.thePOZcast.com CHAPTERS / TIMESTAMPS00:00 – Welcome to RecFest Nashville 2025Adam sets the scene and kicks off day two of #thePOZcast live from the Juicebox.ai booth.00:28 – Guest 1: Steve Levy – The Elder Statesman of Recruiting WisdomSteve shares why RecFest stands apart, how it fosters real community, and why curiosity—not automation—keeps recruiters sharp.02:45 – Learning, Listening, and the Power of CuriositySteve drops classic Levy gems: “Two ears, one mouth—use them proportionally.” A masterclass in humility and experimentation.05:18 – Advice for Job Seekers in a Tough MarketSteve explains why teaching others what you've learned and practicing gratitude are secret weapons for staying visible and relevant.06:57 – Final Word: CommunityThe legendary recruiter sums up RecFest 2025 in one word: Community.08:13 – Guest 2: Brian Petroski (EXP)Director of TA shares insights on recruiting engineers at scale, sourcing tools that work (LinkedIn, HireEZ, Indeed), and standing in line for Nashville's best food truck.10:37 – Guest 3: Leslie Harrah & Kim Johnson (Fortified Health Security)Two powerhouse women in cybersecurity recruiting talk about connecting with people, building culture, and the beauty of the TA community.12:01 – Pivoting Careers & Finding New OpportunitiesAdam shares tactical advice for job seekers on leveraging certifications, curiosity, and career pivots into hot sectors like cybersecurity and clean tech.12:59 – Guest 4: Taylor Hunter (Gaylor Electric)Insights on ATS tools, recruiting high-level talent, and how scraping extensions and sourcing hacks make life easier for busy TA pros.15:23 – Guest 5: Carmen Scanlon (Belong HQ)On startup life, meaningful networking, and the simplicity and depth that make RecFest so special.17:26 – Closing: Gratitude from the FieldAdam wraps from the food trucks with final reflections on connection, learning, and community.
Thanks for listening, and please follow us on Insta @NHPTalent and www.youtube.com/thePOZcastFor all episodes, please check out www.thePOZcast.com Chapter Breakdown00:00 – Welcome to RecFest Nashville 2025Adam sets the scene at the Juicebox.ai booth and kicks off #thePOZcast live from the field.00:28 – Guest 1: Omar Khateeb – The Power of Authentic Video ContentCEO of JobPixel on why “vibe is everything,” how authenticity wins in 2025, and why creators should stop chasing algorithms.02:24 – Survival Tips for RecFestHydrate, eat before noon, and network smarter — Omar's pro tips for surviving outdoor conferences.03:45 – Guest 2: Allyn Bailey – The Heart of Brand Experience at SmartRecruitersAlynn breaks down how storytelling and connection drive talent strategy post-acquisition — and why she proudly calls herself “the class mom” of HR tech.06:54 – Guest 3: Jamie Leonard – The RecFest Origin & Future VisionThe founder himself on why RecFest feels like summer camp for recruiters, the UK vs. US vibes, and what's next (spoiler: Ferris wheel?).10:50 – Guest 4: Vicky Lou – Inside Juicebox.ai's Series A RocketshipThe founding marketer shares what makes Juicebox's AI sourcing platform different, how startup life fuels creativity, and her secret to building high-performing teams.14:49 – Sticker Drop & Shoutout to Juicebox.aiAdam and Vicky unveil the ultra-rare holographic POZcast sticker and talk sponsor love.16:11 – Guest Panel: Nikki Russell, Dan Lockhart & Chantelle LubingerReal-world TA leaders on quality of slate, giving rejection with empathy, and why “we're humans first.”21:44 – Guest 7: John Ruffini – Old School Recruiting Wisdom Meets New TechThe VP of Professional Development at HealthTrust Workforce Solutions explains why recruiters have gotten lazy, how to bring back urgency, and the lost art of the phone call.28:16 – The AI Debate & Juicebox Agents in ActionAdam and John discuss how to use AI as a tool — not a crutch — and how it frees recruiters for the human side of the job.29:09 – Closing Thoughts: Stay Human, Stay HungryAdam wraps from the field with gratitude, laughter, and the promise that wisdom is forever.
Host: Ryan Quigley Guest: Luigi Adamo, MD, PhD Guest: Andrea Fava, MD Fatigue and exercise intolerance in patients with systemic lupus erythematosus (SLE) may persist even when disease activity is controlled, and preload deficiency could be an overlooked cause. In this expert-led discussion, Drs. Luigi Adamo and Andrea Fava share insights from their research, highlighting diagnostic clues, the role of NT-proBNP, and emerging interventions aimed at improving quality of life. Dr. Adamo is an Associate Professor of Medicine and the Director of Cardiac Immunology, and Dr. Fava is an Assistant Professor of Medicine in the Division of Rheumatology and Director of Lupus Translational Research at Johns Hopkins Medicine.
Host: Ryan Quigley Guest: Luigi Adamo, MD, PhD Guest: Andrea Fava, MD Fatigue and exercise intolerance in patients with systemic lupus erythematosus (SLE) may persist even when disease activity is controlled, and preload deficiency could be an overlooked cause. In this expert-led discussion, Drs. Luigi Adamo and Andrea Fava share insights from their research, highlighting diagnostic clues, the role of NT-proBNP, and emerging interventions aimed at improving quality of life. Dr. Adamo is an Associate Professor of Medicine and the Director of Cardiac Immunology, and Dr. Fava is an Assistant Professor of Medicine in the Division of Rheumatology and Director of Lupus Translational Research at Johns Hopkins Medicine.
Guest: Yana Zemkova, MD How often are ICU patients conscious during intubation despite paralysis? Hear from Dr. Yana Zemkova as she discusses new findings on the incidence of awareness with paralysis and the urgent need for improved monitoring in critical care. Dr. Zemkova is Clinical Assistant Professor of Internal Medicine specializing in Pulmonary, Critical Care and Occupational Medicine at the University of Iowa, and she spoke about this topic at the 2025 CHEST Annual Meeting.
Guest: Yana Zemkova, MD How often are ICU patients conscious during intubation despite paralysis? Hear from Dr. Yana Zemkova as she discusses new findings on the incidence of awareness with paralysis and the urgent need for improved monitoring in critical care. Dr. Zemkova is Clinical Assistant Professor of Internal Medicine specializing in Pulmonary, Critical Care and Occupational Medicine at the University of Iowa, and she spoke about this topic at the 2025 CHEST Annual Meeting.
Guest: Gary S. Firestein, MD Despite advances in biologics, many patients with rheumatoid arthritis still experience persistent inflammation. However, cadherin-6 has recently been identified as a potential treatment target. Hear from Dr. Gary Firestein as he explains the discovery, function, and therapeutic potential of cadherin-6 in rheumatoid arthritis pathogenesis. Dr. Firestein is a Distinguished Professor of Medicine and the Senior Associate Vice Chancellor for Health Sciences at UC San Diego.
Guest: Gary S. Firestein, MD While cadherin-6 may not yet shift clinical practice in rheumatoid arthritis, its role as a surface-expressed, actionable target opens the door to rapid therapeutic development—particularly with existing antibodies already in clinical trials for urologic cancers. Dr. Gary Firestein discusses the potential for cadherin-6 to become a useful target across multiple diseases. Dr. Firestein is a Distinguished Professor of Medicine and the Senior Associate Vice Chancellor for Health Sciences at UC San Diego.
Guest: Gary S. Firestein, MD While cadherin-6 may not yet shift clinical practice in rheumatoid arthritis, its role as a surface-expressed, actionable target opens the door to rapid therapeutic development—particularly with existing antibodies already in clinical trials for urologic cancers. Dr. Gary Firestein discusses the potential for cadherin-6 to become a useful target across multiple diseases. Dr. Firestein is a Distinguished Professor of Medicine and the Senior Associate Vice Chancellor for Health Sciences at UC San Diego.
Guest: Gary S. Firestein, MD Despite advances in biologics, many patients with rheumatoid arthritis still experience persistent inflammation. However, cadherin-6 has recently been identified as a potential treatment target. Hear from Dr. Gary Firestein as he explains the discovery, function, and therapeutic potential of cadherin-6 in rheumatoid arthritis pathogenesis. Dr. Firestein is a Distinguished Professor of Medicine and the Senior Associate Vice Chancellor for Health Sciences at UC San Diego.
Guest: Sujith Cherian MD, FCCP, DAABIP Obesity impacts how the lungs function in a variety of ways, and understanding these impacts is essential for interpreting pulmonary function tests, identifying restrictive or obstructive patterns, and managing ventilation. Learn more with Dr. Sujith Cherian, who's an Associate Professor in the Divisions of Critical Care, Pulmonary, and Sleep Medicine at University of Texas Health-McGovern Medical School and the Director of Interventional Pulmonology and Pleural Diseases at Lyndon B. Johnson Hospital in Houston. He also spoke about this topic at the 2025 CHEST Annual Meeting.
Guest: Sujith Cherian MD, FCCP, DAABIP Obesity impacts how the lungs function in a variety of ways, and understanding these impacts is essential for interpreting pulmonary function tests, identifying restrictive or obstructive patterns, and managing ventilation. Learn more with Dr. Sujith Cherian, who's an Associate Professor in the Divisions of Critical Care, Pulmonary, and Sleep Medicine at University of Texas Health-McGovern Medical School and the Director of Interventional Pulmonology and Pleural Diseases at Lyndon B. Johnson Hospital in Houston. He also spoke about this topic at the 2025 CHEST Annual Meeting.
Guest: David Feller-Kopman, MD Cytology via thoracentesis remains the first-line approach for diagnosing malignant pleural effusion (MPE), yet its sensitivity is limited. leaving many patients undiagnosed or delayed in treatment. In this expert-led discussion, Dr. David Feller-Kopman explores the limitations of current diagnostic methods and the evolving role of biomarkers in enhancing both diagnostic accuracy and prognostic insight. Dr. Feller-Kopman is a Professor of Medicine at the Geisel School of Medicine at Dartmouth and the Chief of Pulmonary and Critical Care Medicine at Dartmouth-Hitchcock Medical Center, and he discussed this topic at the 2025 CHEST Annual Meeting.
Guest: David Feller-Kopman, MD Cytology via thoracentesis remains the first-line approach for diagnosing malignant pleural effusion (MPE), yet its sensitivity is limited. leaving many patients undiagnosed or delayed in treatment. In this expert-led discussion, Dr. David Feller-Kopman explores the limitations of current diagnostic methods and the evolving role of biomarkers in enhancing both diagnostic accuracy and prognostic insight. Dr. Feller-Kopman is a Professor of Medicine at the Geisel School of Medicine at Dartmouth and the Chief of Pulmonary and Critical Care Medicine at Dartmouth-Hitchcock Medical Center, and he discussed this topic at the 2025 CHEST Annual Meeting.
Host: Ryan Quigley New research presented at the 2025 American College of Rheumatology Convergence highlights a critical link between adverse childhood experiences and mental health outcomes in adolescents with childhood-onset systemic lupus erythematosus (cSLE). In this AudioAbstract, Ryan Quigley explores the findings, the implications for trauma-informed care, and the need to assess psychosocial history in managing cSLE.
Guest: Jaime Moore, MD Discussing weight with pediatric patients and families is a nuanced challenge shaped by stigma, culture, and access—but it's also a vital opportunity for early intervention. Dr. Jaime Moore shares how to build confidence, counter bias, and leverage practical tools and partnerships that support long-term, personalized care. Dr. Moore is an Assistant Professor of Pediatric Nutrition at the University of Colorado Anschutz School of Medicine and part of the Children's Hospital Colorado Lifestyle Medicine Program. She also spoke about this topic at the 2025 American Academy of Pediatrics (AAP) National Conference and Exhibition.
Guest: Jaime Moore, MD Discussing weight with pediatric patients and families is a nuanced challenge shaped by stigma, culture, and access—but it's also a vital opportunity for early intervention. Dr. Jaime Moore shares how to build confidence, counter bias, and leverage practical tools and partnerships that support long-term, personalized care. Dr. Moore is an Assistant Professor of Pediatric Nutrition at the University of Colorado Anschutz School of Medicine and part of the Children's Hospital Colorado Lifestyle Medicine Program. She also spoke about this topic at the 2025 American Academy of Pediatrics (AAP) National Conference and Exhibition.
Host: Ryan Quigley New research presented at the 2025 American College of Rheumatology Convergence highlights a critical link between adverse childhood experiences and mental health outcomes in adolescents with childhood-onset systemic lupus erythematosus (cSLE). In this AudioAbstract, Ryan Quigley explores the findings, the implications for trauma-informed care, and the need to assess psychosocial history in managing cSLE.
Guest: Eric Ruderman, MD Combined dermatology–rheumatology clinics are transforming psoriatic disease care by streamlining communication, reducing patient burden, and enabling more targeted, effective treatments. To learn more about how these clinks work and why they matter for patients with psoriatic disease, tune in to hear from Dr. Eric Ruderman, Professor of Medicine and the Associate Chief of Clinical Affairs for the Division of Rheumatology at Northwestern University Feinberg School of Medicine.
Guest: Eric Ruderman, MD Combined dermatology–rheumatology clinics are transforming psoriatic disease care by streamlining communication, reducing patient burden, and enabling more targeted, effective treatments. To learn more about how these clinks work and why they matter for patients with psoriatic disease, tune in to hear from Dr. Eric Ruderman, Professor of Medicine and the Associate Chief of Clinical Affairs for the Division of Rheumatology at Northwestern University Feinberg School of Medicine.
Host: Ryan Quigley In a 2025 study investigating salivary metabolites as potential biomarkers in cystic fibrosis, researchers identified distinct metabolic patterns linked with key complications as well as correlations with lung function. In this AudioAbstract, Ryan Quigley discusses how a simple saliva sample could provide clinicians with an accessible, non-invasive tool to stratify patients, monitor therapies, and advance personalized care in cystic fibrosis. This topic was also discussed at the 2025 CHEST Annual Meeting.
Host: Ryan Quigley In a 2025 study investigating salivary metabolites as potential biomarkers in cystic fibrosis, researchers identified distinct metabolic patterns linked with key complications as well as correlations with lung function. In this AudioAbstract, Ryan Quigley discusses how a simple saliva sample could provide clinicians with an accessible, non-invasive tool to stratify patients, monitor therapies, and advance personalized care in cystic fibrosis. This topic was also discussed at the 2025 CHEST Annual Meeting.
Host: Ryan Quigley Guest: Heather Forkey, MD Guest: Wynne Morgan, MD Childhood trauma can profoundly alter brain and behavioral development, making it essential to recognize how trauma differs from other diagnoses like ADHD. Ryan Quigley sits down with Drs. Heather Forkey and Wynne Morgan, who presented on this topic at the 2025 American Academy of Pediatrics National Conference and Exhibition, to better understand how to identify trauma responses, avoid misdiagnosis, and implement supportive treatment strategies that prioritize safety, routine, and caregiver connection. Dr. Forkey is a Professor of Pediatrics and Vice Chair of Pediatrics and Dr. Morgan is an Assistant Professor in the Departments of Psychiatry and Behavioral Sciences at UMass Chan Medical School in Worcester, Massachusetts.
Guest: Jennifer M. Kalish, MD, PhD, FAAP Early genetic evaluation plays a vital role in identifying potential causes of neurodevelopmental disorders and guiding families on next steps, expectations, and recurrence risks. Dr. Jennifer Kalish joins us to share practical insights for recognizing when to initiate testing, selecting the right tests, and addressing barriers such as insurance and interpretation. Dr. Kalish is an Assistant Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine and the Director of the Beckwith-Wiedemann Syndrome Program at the Children's Hospital of Philadelphia. She also spoke about this topic at the 2025 American Academy of Pediatrics (AAP) National Conference and Exhibition.
Host: Shelina Ramnarine, PhD Guest: Yolanda N. Evans, MD, FAAP Recognizing how inequities can significantly impact pediatric care outcomes is essential to improving access, trust, and long-term health. Dr. Shelina Ramnarine is joined by Dr. Yolanda Evans to discuss actionable strategies that can help us deliver more inclusive care, from social determinant screeners to equity-focused frameworks. Dr. Evans is a board-certified pediatrician and adolescent medicine specialist practicing in Seattle, Washington, and she spoke about this topic at the 2025 American Academy of Pediatrics National Conference and Exhibition.
Host: Ryan Quigley Guest: Heather Forkey, MD Guest: Wynne Morgan, MD Childhood trauma can profoundly alter brain and behavioral development, making it essential to recognize how trauma differs from other diagnoses like ADHD. Ryan Quigley sits down with Drs. Heather Forkey and Wynne Morgan, who presented on this topic at the 2025 American Academy of Pediatrics National Conference and Exhibition, to better understand how to identify trauma responses, avoid misdiagnosis, and implement supportive treatment strategies that prioritize safety, routine, and caregiver connection. Dr. Forkey is a Professor of Pediatrics and Vice Chair of Pediatrics and Dr. Morgan is an Assistant Professor in the Departments of Psychiatry and Behavioral Sciences at UMass Chan Medical School in Worcester, Massachusetts.
Host: Shelina Ramnarine, PhD Guest: Yolanda N. Evans, MD, FAAP Recognizing how inequities can significantly impact pediatric care outcomes is essential to improving access, trust, and long-term health. Dr. Shelina Ramnarine is joined by Dr. Yolanda Evans to discuss actionable strategies that can help us deliver more inclusive care, from social determinant screeners to equity-focused frameworks. Dr. Evans is a board-certified pediatrician and adolescent medicine specialist practicing in Seattle, Washington, and she spoke about this topic at the 2025 American Academy of Pediatrics National Conference and Exhibition.
Guest: Jennifer M. Kalish, MD, PhD, FAAP Early genetic evaluation plays a vital role in identifying potential causes of neurodevelopmental disorders and guiding families on next steps, expectations, and recurrence risks. Dr. Jennifer Kalish joins us to share practical insights for recognizing when to initiate testing, selecting the right tests, and addressing barriers such as insurance and interpretation. Dr. Kalish is an Assistant Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine and the Director of the Beckwith-Wiedemann Syndrome Program at the Children's Hospital of Philadelphia. She also spoke about this topic at the 2025 American Academy of Pediatrics (AAP) National Conference and Exhibition.
Guest: Michael Levy, MD, PhD Antibody-mediated demyelinating diseases, such as neuromyelitis optica spectrum disorder and MOG antibody disease, differ fundamentally from multiple sclerosis (MS) due to their association with specific antibodies. Dr. Michael Levy explains how these conditions progress, how relapses can drive disability, and why prevention is critical for improving long-term outcomes. Dr. Levy is an Associate Professor at Harvard Medical School working in the Department of Neurology at Brigham and Women's Hospital, and he spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.
Guest: Sergio Baranzini, PhD In a landmark study involving over 10,000 patients, the International MS Genetics Consortium (IMSGC) has identified the first genetic variant associated with disease severity in multiple sclerosis (MS). Dr. Sergio Baranzini, a Distinguished Professor of Neurology at the University of California, San Francisco Weill Institute for Neurosciences, explains what's next in researching this variant and working towards effective treatments. Dr. Baranzini also spoke on this topic at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Guest: Sergio Baranzini, PhD In a landmark study involving over 10,000 patients, the International MS Genetics Consortium (IMSGC) has identified the first genetic variant associated with disease severity in multiple sclerosis (MS). Dr. Sergio Baranzini, a Distinguished Professor of Neurology at the University of California, San Francisco Weill Institute for Neurosciences, explains what's next in researching this variant and working towards effective treatments. Dr. Baranzini also spoke on this topic at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Guest: Le Hua, MD Diagnosing multiple sclerosis (MS) in older patients presents unique challenges, especially as age-related comorbidities and common neurological findings often mimic MS. Hear from Dr. Le Hua as she highlights the importance of thorough clinical history, cautious interpretation of imaging, and the role of paraclinical studies in ensuring accurate MS diagnosis, particularly in patients over 50. Dr. Hua is the Director of Clinical Operations and Director of the Multiple Sclerosis Program at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. She also spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.
Guest: Le Hua, MD Diagnosing multiple sclerosis (MS) in older patients presents unique challenges, especially as age-related comorbidities and common neurological findings often mimic MS. Hear from Dr. Le Hua as she highlights the importance of thorough clinical history, cautious interpretation of imaging, and the role of paraclinical studies in ensuring accurate MS diagnosis, particularly in patients over 50. Dr. Hua is the Director of Clinical Operations and Director of the Multiple Sclerosis Program at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. She also spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.
Guest: Sergio Baranzini, PhD In a landmark study involving over 10,000 patients, the International MS Genetics Consortium (IMSGC) has identified the first genetic variant associated with disease severity in multiple sclerosis (MS). Dr. Sergio Baranzini, a Distinguished Professor of Neurology at the University of California, San Francisco Weill Institute for Neurosciences, explains what's next in researching this variant and working towards effective treatments. Dr. Baranzini also spoke on this topic at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Guest: Michael Levy, MD, PhD Antibody-mediated demyelinating diseases, such as neuromyelitis optica spectrum disorder and MOG antibody disease, differ fundamentally from multiple sclerosis (MS) due to their association with specific antibodies. Dr. Michael Levy explains how these conditions progress, how relapses can drive disability, and why prevention is critical for improving long-term outcomes. Dr. Levy is an Associate Professor at Harvard Medical School working in the Department of Neurology at Brigham and Women's Hospital, and he spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.
Guest: Michael Levy, MD, PhD Antibody-mediated demyelinating diseases, such as neuromyelitis optica spectrum disorder and MOG antibody disease, differ fundamentally from multiple sclerosis (MS) due to their association with specific antibodies. Dr. Michael Levy explains how these conditions progress, how relapses can drive disability, and why prevention is critical for improving long-term outcomes. Dr. Levy is an Associate Professor at Harvard Medical School working in the Department of Neurology at Brigham and Women's Hospital, and he spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.
Guest: Le Hua, MD Diagnosing multiple sclerosis (MS) in older patients presents unique challenges, especially as age-related comorbidities and common neurological findings often mimic MS. Hear from Dr. Le Hua as she highlights the importance of thorough clinical history, cautious interpretation of imaging, and the role of paraclinical studies in ensuring accurate MS diagnosis, particularly in patients over 50. Dr. Hua is the Director of Clinical Operations and Director of the Multiple Sclerosis Program at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. She also spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.
Guest: Leonard Calabrese, DO Preventing serious infections should be a priority when treating patients with immune-mediated inflammatory diseases, especially those receiving immunosuppressive therapies. By assessing patients' level of immunocompetence, clinicians can better tailor vaccination strategies and optimize infection prevention. Hear Dr. Leonard Calabrese discuss how to evaluate immunosuppression risk and coordinate timely vaccinations for patients undergoing immunomodulatory treatments. Dr. Calabrese heads the Section of Clinical Immunology at the Cleveland Clinic in Ohio, where he manages the Clinical Immunology Clinic and is on the staff of the Department of Rheumatic and Immunologic Diseases. He also spoke on this topic at the 2025 Congress of Clinical Rheumatology West conference.
Guest: Laura B. Enyedi, MD Pediatricians are often the first to encounter eye conditions that can range from common to life-threatening. Hear from Dr. Laura Enyedi as she shares highlights from her presentation on diagnosing childhood ocular disorders from the 2025 American Academy of Pediatrics (AAP) National Conference and Exhibition. Dr. Enyedi is a Professor of Ophthalmology and an Associate Professor in Pediatrics at Duke University School of Medicine in Durham, North Carolina.
Host: Hallie Blevins, PhD. Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these findings were later validated in the HU-F-AIM trial. Hear from ReachMD's Dr. Hallie Blevins as she dives into the results and explains implications for optimized therapy and improved long-term outcomes.
Host: Ryan Quigley In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.
Host: Marlene Mimi Maeusli, PhD. A recent Danish population-based study evaluating real-world outcomes of ibrutinib in relapsed or refractory mantle cell lymphoma (MCL) found lower efficacy and tolerability compared to clinical trials, particularly among older patients and those with high-risk disease features. In this AudioAbstract, ReachMD's Dr. Mimi Maeusli explains how this evidence is reshaping our view of ibrutinib's clinical utility.
Guest: Paola Marignani, PhD, EMBA While smoking remains a key risk factor for lung cancer, up to 25 percent of cases occur in people who have never smoked, leaving significant gaps in our understanding of causation and diagnostics. Dr. Paola Marignani explores emerging discoveries in gene variants unique to never-smokers, uncovered through single-cell RNA sequencing and machine learning. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.
Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.
Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.
Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.
Guest: Paola Marignani, PhD, EMBA Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diversity, predictive modeling for recurrence and drug resistance, and personalized treatment strategies. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.
Hear from experts in HIV care Beatriz Grinsztejn, MD, PhD, and Rosie Mnggibisa, MBChB, MPH, as they discuss their insights on some of the most clinically relevant new data presented at IAS 2025, including studies on: Gaps in care for adolescents and young adults living with HIVGlobal impact of funding cutsAntiretroviral therapy for treating HIVPatient management strategies for people living with HIV and obesityPresenters:Beatriz Grinsztejn, MD, PhDDirectorSTI/HIV Clinical Research LaboratoryEvandro Chagas National Institute of Infectious Diseases – FIOCRUZRio de Janeiro, BrazilRosie Mngqibisa, MBChB, MPHClinical DirectorPrincipal InvestigatorEnhancing Care FoundationDurban, South AfricaLink to full program: https://bit.ly/4otF8AR
In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCLECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCLCADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLLInMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FLSHR2554: Oral EZH2 Inhibitor in R/R PTCLSYRUS: AZD0486 Bispecific Antibody for R/R B-ALLPresenters:Max S. Topp, MDHead of Hematology and Clinical CAR-T Program LeadAssociated ProfessorMedinische Klinik und Poliklinkik IIUniversity of WurzburgWurzburg, GermanyPier Luigi Zinzani, MD, PhDProfessor of HematologyAlma Mater Studiorum- University of BolognaHead, “Seràgnoli” Institute of HematologyIRCCS Azienda Ospedaliero-Universitaria di BolognaDepartment of Medical and Surgical SciencesBologna University School of MedicineBologna, ItalyLink to full program:https://bit.ly/4obcJPI
In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including: DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic breast cancerASCENT-04/KEYNOTE-D19: phase III trial of first-line sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in PD-L1–positive advanced TNBCSERENA-6: phase III trial of ctDNA-guided switch to camizestrant plus CDK4/6i vs continued AI plus CDK4/6i following ESR1 mutation emergence in HR-positive/HER2-negative advanced breast cancerINAVO120: OS from phase III study of first-line inavolisib/PBO plus palbociclib plus fulvestrant in PIK3CA-mutated, HR-positive/HER2-negative, endocrine-resistant advanced breast cancerPresenters:Kevin Kalinsky, MD, MS, FASCOProfessor of MedicineLouisa and Rand Glenn Family Chair in Breast Cancer ResearchWinship Cancer InstituteEmory UniversityAtlanta, GeorgiaSara M. Tolaney, MD, MPHChief, Breast OncologyDana-Farber Cancer InstituteAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME program supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.Link to full program: https://bit.ly/4lFS4BC